Meta-analysis and trial sequential analysis of the effects of SGLT2 inhibitors on cardiovascular adverse events in type 2 diabetes mellitus patients with cardiovascular disease#br#
ZHOU Xinrong1 LI Yan1 ZHU Jiajun1 WANG Ning2▲
1.Cardiovascular Center Intensive Care Unit, the First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi 830054, China;
2.Department of General Second Internal Medicine, the First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi 830054, China
Abstract：Objective To evaluate the effects of sodium-glucose linked transporter 2 (SGLT2) inhibitors on cardiovascular adverse events in type 2 diabetes mellitus patients with cardiovascular disease. Methods PubMed, Cochrane Library, Google Scholar, Wanfang Data, CNKI, and Chinese Biomedical Database were searched for randomized controlled trial (RCT) on the effects of SGLT2 inhibitors on cardiovascular adverse events in type 2 diabetes mellitus patients with cardiovascular disease. The retrieval period is from the inception to April 2021. Meta-analysis, sequential analysis, and evidence quality evaluation were performed by RevMan, TSA, and GRADE pro, respectively. Results Six RCTs were included, with a total of 30 534 patients. Meta-analysis showed that cardiovascular mortality rate (RR = 0.84, 95%CI: 0.72-0.99, P = 0.03), hospitalization rate for heart failure (RR = 0.67, 95%CI: 0.60-0.73, P ＜ 0.000 01), and all-cause mortality (RR = 0.85, 95%CI: 0.78-0.92, P ＜ 0.0001) were lower than those in placebo group. GRADE evidence quality evaluation results showed that the quality GRADE of meta-analysis results was “high”. The sequential analysis results showed that the meta-analysis results were relatively positive and did not need to be proved by more experiments. Conclusion SGLT2 inhibitors plays a good cardioprotective role in type 2 diabetes mellitus patients with cardiovascular disease.
周欣荣1 李艳1 朱嘉俊1 王宁2▲. SGLT2抑制剂对2型糖尿病合并心血管疾病患者心血管不良事件影响的meta分析与试验序贯分析[J]. 中国医药导报, 2022, 19(8): 64-68.
ZHOU Xinrong1 LI Yan1 ZHU Jiajun1 WANG Ning2▲. Meta-analysis and trial sequential analysis of the effects of SGLT2 inhibitors on cardiovascular adverse events in type 2 diabetes mellitus patients with cardiovascular disease#br#. 中国医药导报, 2022, 19(8): 64-68.
京公网安备 11010502046598号